Elevated intraocular pressure (IOP) is a major risk factor for glaucoma; thus, individuals with ocular hypertension (OHT) are considered to have a greater chance of developing the condition. The primary standard therapy in patients with open-angle glaucoma or ocular hypertension is topical medication to lower IOP. Typically, patients are treated with a single medication at the onset of treatment, so called monotherapy. Many times, monotherapy doesn’t achieve target IOP. That’s when doctors will prescribe additional products as adjunctive therapy.

Three highly respected thought leaders gathered at a recent industry meeting to talk about a fi xed-combination treatment for elevated IOP, SIMBRINZA® (brinzolamide/ brimonidine tartrate ophthalmic suspension 1%/0.2%, Alcon). The following monograph outlines their discussion, which includes the drug’s indications, warnings and precautions associated with it, results of pivotal Phase III trials and more.